Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2012
March 2012, Vol 3, No 2
March 2012, Vol 3, No 2
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—A novel inhibitor of B-cell receptor signaling, PCI-32765, produced high rates of remission and was well tolerated in patients with chronic lymphocytic leukemia (CLL) whose disease was refractory to at least 2 previous treatments, reported Susan O'Brien, MD, of the University of Texas M.D. Anderson Cancer Center, Houston.
Read Article
Lymphoma Treatment in Pregnancy Does Not Compromise Fetal/Maternal Outcomes
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—The treatment of lymphoma during pregnancy does not compromise fetal outcomes or maternal health and cancer-specific survival, according to a study presented at ASH 2011 from the University of Massachusetts Medical School in Worcester.
Read Article
Chemotherapy Superior to Radiation for Nonbulky Hodgkin Lymphoma, but Older Radiotherapy Method Was Evaluated
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
In patients with early-stage, nonbulky Hodgkin lymphoma (HL), overall survival (OS) was superior at 12 years in patients who received standard chemotherapy compared with radiotherapy in a study conducted by the National Cancer Institute of Canada's Clinical Trials Group and the Eastern Cooperative Oncology Group.
Read Article
Confusion Still Surrounds Prophylaxis for Venous Thromboembolism
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—Venous thromboembolism (VTE) occurs in 1% of hematologic malignancies and can lead to fatal pulmonary emboli, postthrombotic syndromes, bleeding as a result of anticoagulant treatment, and recurrent VTE.
Read Article
High-Risk Myelodysplastic Syndrome: First-Line Treatment Choices Often Not Supported by Evidence
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
A review of treatment patterns for higher-risk myelodysplastic syndrome (MDS) shows growing use of lenalidomide, despite the lack of phase 3 survival data supporting this approach, according to research conducted at the Mayo Clinic Florida, Jacksonville, in collaboration with Xcenda, a research and consulting firm.
Read Article
Cryoprecipate Is Overused, an Unnecessary Expense
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—Only 30% of cryoprecipitate was used in accordance with established guidelines in a tertiary care center, in a study presented at ASH 2011 by researchers from Beth Israel Medical Center, Newark, NJ.
Read Article
Can Value-Based Cancer Care Address the Challenges Faced by Specialty Pharmacies in Oncology?
By
Atheer A. Kaddis, PharmD
Economics & Value
,
Value-Based Care
,
VBCC Perspectives
March 2012, Vol 3, No 2
Specialty pharmacies are facing specific challenges in the ways they interact with payers, providers, and even with the pharmaceutical industry in relation to access and delivery of cancer drugs.
Read Article
Chemotherapy Administration Sequencing Chart
Chemotherapy
,
Personalized Medicine
March 2012, Vol 3, No 2
We conducted a literature search for data supporting same-day chemotherapy administration sequences. This was achieved by searching PubMed using keywords and any combination of the drug name with "administration," "sequencing," or "interactions."
Read Article
Vismodegib: A New Treatment Option for Basal-Cell Carcinoma
By
Rhonda Williams
Cancer Drugs
,
Personalized Medicine
March 2012, Vol 3, No 2
Basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC), commonly referred to as non-melanoma skin cancers (NMSCs), are the most common types of cancers in the United States. These 2 cancers account for approximately 2 million cases of skin cancer annually.
Read Article
The End of Health Insurance Companies
By
Ezekiel J. Emanuel
Health Policy
,
Policies & Guidelines
March 2012, Vol 3, No 2
Here’s a bold prediction for the new year. By 2020, the American health insurance industry will be extinct. Insurance companies will be replaced by accountable care organizations (ACOs) —groups of doctors, hospitals and other health care providers who come together to provide the full range of medical care for patients.
Read Article
Page 4 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma